Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial

BACKGROUND: Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax combined with azacitidine plus homoharringtonine (VAH) regimen for R/R AML. METHODS: This phase 2 trial was done at ten hos...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Hua, Zhang, Yu, Yu, Sijian, Du, Xin, Xu, Na, Shao, Ruoyang, Lin, Dongjun, Chen, Yanqiu, Xiao, Jie, Sun, Zhiqiang, Deng, Lan, Liang, Xinquan, Zhang, Hongyu, Guo, Ziwen, Dai, Min, Shi, Pengcheng, Huang, Fen, Fan, Zhiping, Yin, Zhao, Xuan, Li, Lin, Ren, Jiang, Xuejie, Yu, Guopan, Liu, Qifa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149010/
https://www.ncbi.nlm.nih.gov/pubmed/37120593
http://dx.doi.org/10.1186/s13045-023-01437-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149010/
https://www.ncbi.nlm.nih.gov/pubmed/37120593
http://dx.doi.org/10.1186/s13045-023-01437-1

Ejemplares similares